유전자 편집 시장 규모, 점유율, 동향 분석 리포트 : 기술별, 전달 방법별, 용도별, 모드별, 최종 용도별, 지역별, 부문 예측(2024-2030년)

Genome Editing Market Growth & Trends:

The global genome editing market size is expected to reach USD 25.00 billion by 2030, exhibiting a CAGR of 16.94% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing advancements in genome editing technology, the growing funding & investments in the genomics industry, the increasing prevalence of genetic disorders, and the need for improved treatments and therapies are major factors driving revenue growth.

The evolution of genome editing technologies is another contributing factor to drive revenue growth in the market. Most effective and accurate gene editing is now possible through the enhancement of new and advanced genome editing methods including CRISPR-Cas13,prime editing, and base editing, amongst others. This creates genome editing methods used more often in academic and medical contexts. For instance, in January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools & reagents.

The increasing application of gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor revenue generation in the foreseeable future. Research communities are exploring the potential of gene-modification instruments such as CRISPR as a potential fast screening solution for various chronic diseases. Such research programs are likely to benefit the market for genome editing in the coming years.

Genome Editing Market Report Highlights:

• By technology, The CRISPR/Cas9 segment held the largest market share of 43.52% of the global revenue in 2023.
• The ex-vivo segment dominated the market with a share of 51.24% in 2023. This dominance can be attributed to the ease of control in DNA modification provided along with the precise regulation of strength and duration of nuclease expression to minimize off-target editing and maximize efficiency.
• The genetic engineering segment held the largest market share in 2023. The segment is further categorized into cell line engineering, animal genetic engineering, plant genetic engineering, and others.
• The contract segment dominated the market in 2023 due to the high extent of outsourcing activities in the genomics space driven by the lower costs and greater flexibility in operations offered by such activities as compared to in-house development.
• The biotechnology and pharmaceutical companies segment accounted for the largest market share of 50.95% in 2023.
• North America dominated the market and accounted for a 47.81% share in 2023 owing to the growing investments in the R&D of gene editing technologies.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology Segment
  • 1.2.2. Delivery Method Segment
  • 1.2.3. Application Segment
  • 1.2.4. Mode Segment
  • 1.2.5. End-use Segment
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Genome Editing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Success in pre-clinical models drives demand for genome editing therapeutics
    • 3.2.1.2. Rising competition amongst market participants for business development
    • 3.2.1.3. Easy editing solutions for the development of therapeutics for a broad range of diseases
    • 3.2.1.4. Increasing demand for synthetic genes and genetically modified organisms
    • 3.2.1.5. Technological advancements in gene editing technologies
    • 3.2.1.6. Rising adoption in agricultural biotechnology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Challenges concerning clinical translation
    • 3.2.2.2. Regulatory, scientific, and ethical challenges regarding the use of genetically modified products
    • 3.2.2.3. Off-target effects of CRISPR technology
• 3.3. Genome Editing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Genome Editing Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Genome Editing Market Technology Movement Analysis
• 4.3. Global Genome Editing Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. (CRISPR)/Cas9
  • 4.4.1. (CRISPR)/Cas9 market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. TALENs/MegaTALs
  • 4.5.1. TALENs/MegaTALs market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. ZFN
  • 4.6.1. ZFN market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Meganuclease
  • 4.7.1. Meganuclease market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Genome Editing Market: Delivery Method Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Genome Editing Market Delivery Method Movement Analysis
• 5.3. Global Genome Editing Market Size & Trend Analysis, by Delivery Method, 2018 to 2030 (USD Million)
• 5.4. Ex-vivo
  • 5.4.1. Ex-vivo market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. In-Vivo
  • 5.5.1. In-vivo market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Genome Editing Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Genome Editing Market Application Movement Analysis
• 6.3. Global Genome Editing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Genetic Engineering
  • 6.4.1. Genetic Engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Cell Line Engineering
    • 6.4.2.1. Cell line engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Animal Genetic Engineering
    • 6.4.3.1. Animal genetic engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Plant Genetic Engineering
    • 6.4.4.1. Plant genetic engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Others
    • 6.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Clinical Applications
  • 6.5.1. Clinical applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Diagnostics
    • 6.5.2.1. Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Therapy Development
    • 6.5.3.1. Therapy development market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Genome Editing Market: Mode Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Genome Editing Market Mode Movement Analysis
• 7.3. Global Genome Editing Market Size & Trend Analysis, by Mode, 2018 to 2030 (USD Million)
• 7.4. Contract
  • 7.4.1. Contract market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. In-house
  • 7.5.1. In-house market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Genome Editing Market: End-use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Genome Editing Market End-use Movement Analysis
• 8.3. Global Genome Editing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
• 8.4. Biotechnology and pharmaceutical companies
  • 8.4.1. Biotechnology and pharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Academic and government research institutes
  • 8.5.1. Academic and government research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Contract research organizations
  • 8.6.1. Contract research organizations market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Genome Editing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. U.S.
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework
    • 9.4.1.3. Target disease prevalence
    • 9.4.1.4. Competitive scenario
    • 9.4.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. Canada
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Target disease prevalence
    • 9.4.2.4. Competitive scenario
    • 9.4.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 9.5. Europe
  • 9.5.1. UK
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework
    • 9.5.1.3. Target disease prevalence
    • 9.5.1.4. Competitive scenario
    • 9.5.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Germany
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Target disease prevalence
    • 9.5.2.4. Competitive scenario
    • 9.5.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. France
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Target disease prevalence
    • 9.5.3.4. Competitive scenario
    • 9.5.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Italy
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Target disease prevalence
    • 9.5.4.4. Competitive scenario
    • 9.5.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.5. Spain
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Target disease prevalence
    • 9.5.5.4. Competitive scenario
    • 9.5.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.6. Norway
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Target disease prevalence
    • 9.5.6.4. Competitive scenario
    • 9.5.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.7. Sweden
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Target disease prevalence
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Competitive scenario
    • 9.5.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.8. Denmark
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Regulatory framework
    • 9.5.8.3. Target disease prevalence
    • 9.5.8.4. Competitive scenario
    • 9.5.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Japan
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework
    • 9.6.1.3. Target disease prevalence
    • 9.6.1.4. Competitive scenario
    • 9.6.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. China
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Target disease prevalence
    • 9.6.2.4. Competitive scenario
    • 9.6.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. India
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Target disease prevalence
    • 9.6.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. Australia
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Target disease prevalence
    • 9.6.4.4. Competitive scenario
    • 9.6.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. South Korea
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Target disease prevalence
    • 9.6.5.4. Competitive scenario
    • 9.6.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Thailand
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Target disease prevalence
    • 9.6.6.3. Regulatory framework
    • 9.6.6.4. Competitive scenario
    • 9.6.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Latin America
  • 9.7.1. Brazil
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework
    • 9.7.1.3. Target disease prevalence
    • 9.7.1.4. Competitive scenario
    • 9.7.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. Mexico
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Target disease prevalence
    • 9.7.2.4. Competitive scenario
    • 9.7.2.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Target disease prevalence
    • 9.7.3.4. Competitive scenario
    • 9.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. MEA
  • 9.8.1. South Africa
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Target disease prevalence
    • 9.8.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.2. Saudi Arabia
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework
    • 9.8.2.3. Target disease prevalence
    • 9.8.2.4. Competitive scenario
    • 9.8.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. UAE
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework
    • 9.8.3.3. Target disease prevalence
    • 9.8.3.4. Competitive scenario
    • 9.8.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.4. Kuwait
    • 9.8.4.1. Key country dynamics
    • 9.8.4.2. Regulatory framework
    • 9.8.4.3. Target disease prevalence
    • 9.8.4.4. Competitive scenario
    • 9.8.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2023
• 10.4. Company Profiles/Listing
  • 10.4.1. Merck KGaA
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Cibus Inc
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Recombinetics
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Sangamo Therapeutics
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Editas Medicine
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Precision BioSciences
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. CRISPR Therapeutics
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Intellia Therapeutics, Inc
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Caribou Biosciences, Inc.
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Cellectis S.A
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives
  • 10.4.11. AstraZeneca
    • 10.4.11.1. Company overview
    • 10.4.11.2. Financial performance
    • 10.4.11.3. Product benchmarking
    • 10.4.11.4. Strategic initiatives
  • 10.4.12. Takara Bio Inc.
    • 10.4.12.1. Company overview
    • 10.4.12.2. Financial performance
    • 10.4.12.3. Product benchmarking
    • 10.4.12.4. Strategic initiatives
  • 10.4.13. Horizon Discovery Ltd. (Revvity, Inc.)
    • 10.4.13.1. Company overview
    • 10.4.13.2. Financial performance
    • 10.4.13.3. Product benchmarking
    • 10.4.13.4. Strategic initiatives
  • 10.4.14. Danaher Corporation
    • 10.4.14.1. Company overview
    • 10.4.14.2. Financial performance
    • 10.4.14.3. Product benchmarking
    • 10.4.14.4. Strategic initiatives
  • 10.4.15. Transposagen Biopharmaceuticals, Inc.
    • 10.4.15.1. Company overview
    • 10.4.15.2. Financial performance
    • 10.4.15.3. Product benchmarking
    • 10.4.15.4. Strategic initiatives
  • 10.4.16. Genscript Biotech Corp
    • 10.4.16.1. Company overview
    • 10.4.16.2. Financial performance
    • 10.4.16.3. Product benchmarking
    • 10.4.16.4. Strategic initiatives
  • 10.4.17. New England Biolabs
    • 10.4.17.1. Company overview
    • 10.4.17.2. Financial performance
    • 10.4.17.3. Product benchmarking
    • 10.4.17.4. Strategic initiatives
  • 10.4.18. OriGene Technologies, Inc.
    • 10.4.18.1. Company overview
    • 10.4.18.2. Financial performance
    • 10.4.18.3. Product benchmarking
    • 10.4.18.4. Strategic initiatives
  • 10.4.19. bluebird bio, Inc
    • 10.4.19.1. Company overview
    • 10.4.19.2. Financial performance
    • 10.4.19.3. Product benchmarking
    • 10.4.19.4. Strategic initiatives
  • 10.4.20. Lonza
    • 10.4.20.1. Company overview
    • 10.4.20.2. Financial performance
    • 10.4.20.3. Product benchmarking
    • 10.4.20.4. Strategic initiatives
  • 10.4.21. Thermo Fisher Scientific, Inc.
    • 10.4.21.1. Company overview
    • 10.4.21.2. Financial performance
    • 10.4.21.3. Product benchmarking
    • 10.4.21.4. Strategic initiatives